OClawVPS.com
Gilead Sciences
Edit

Gilead Sciences

http://www.gilead.com/
Last activity: 07.04.2026
Active
Categories: BioTechDrugsHealthcarePharmaceuticalResearch
The way we see it, the impossible is not impossible. It’s simply what hasn’t been achieved yet. For more than 30 years, we’ve pursued it, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases.

Creating Possible drives everything we do. It’s evident in our mission and core values. This is how we built a culture of excellence that is fueled by a passion for improving lives of people around the world.

For us, nothing is impossible – because of the people we work with, the communities we stand with and the partners we push forward with. Our ~12,000 employees band together through science, grit, compassion and courage to prove the impossible wrong.

At Gilead, the tangible results of your contributions are evident. Where every individual matters. Where all employees can enhance their skills through ongoing development. And where we start every day with one question: “What’s next?”
Likes
20.66K
Followers
408.2K
Website visits
726.4K /mo.
Mentions
434
Location: United States
Employees: 10001+
Phone: +1 650-574-3000
Total raised: $304M
Founded date: 1987

Investors 9

Funding Rounds 2

DateSeriesAmountInvestors
17.04.2024Grant$4M-
21.07.2020-$300M-

Mentions in press and media 434

DateTitleDescription
07.04.2026Gilead приобретает немецкого производителя противораковых препаратов Tubulis за $5 млрдВо вторник американская фармкомпания Gilead объявила о планах приобретения частной немецкой компании Tubulis GmbH за сумму до $5 млрд. Сделка направлена на расширение портфеля компании за счет перспективного класса экспериментальных противо...
26.03.2026Keymed Biosciences Announces 2025 Annual Results and Business UpdatesBEIJING, March 26, 2026 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced its 2025 annual results. The year marked the company's 10th anniversary and a pivotal year in its transition from R&D to commercialization. Revenue Leaps...
24.03.2026Gilead покупает Ouro Medicines более чем за $2 млрд и усиливает ставку на иммунологиюПо условиям сделки Gilead выплатит инвесторам Ouro $1,68 млрд авансом наличными, а также еще до $500 млн в случае достижения определенных этапов разработки препарата. Ключевым активом в этой покупке является экспериментальный препарат OM336...
17.03.2026Manta Cares and Gilead Sciences Collaborate to Support Patients Navigating Metastatic Lung and Breast CancerCollaboration spans implementation pilots, evidence generation, and nationwide distribution of customized navigation tools for lung and breast cancer SAN FRANCISCO, March 17, 2026 /PRNewswire-PRWeb/ -- Manta Cares, an award-winning digital ...
14.03.2026ORO Labs Secures $100M to Revolutionize Enterprise AI ProcurementORO Labs, an AI-driven procurement orchestration leader, secured $100 million in Series C funding. This capital injection follows a year of 300% revenue growth. The platform modernizes enterprise procurement. It streamlines complex global s...
12.03.2026ORO Labs raises $100M to expand procurement orchestration platform Send us a News Tip EXTRACT THE SIGNAL FROM THE NOISE CookiesProcurement orchestration platform company ORO Labs Inc. announced today that it has raised $100 million in new funding to accelerate its expansion, further develop its product and scale up customer success and deployment worldwide. Founded...
03.03.2026Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global PlatformNEW YORK, March 3, 2026 /PRNewswire/ -- Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty ...
27.02.2026Gilead Dominates Cell Therapy: $7.8 Billion Arcellx Acquisition Seals FutureGilead Sciences acquired Arcellx for up to $7.8 billion. This landmark acquisition secures full control of anito-cel, a potentially transformative BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. Anito-cel await...
26.02.2026Novartis, Genentech file suit alleging illegal importation of prescription drugNovartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine. The importation of the drug, which has strict shipping and temperature controls, potentially puts ...
26.02.2026Lessons from COVID-19: How Agile Governance is Transforming Pharmaceutical Launch ReadinessGeorge Stephen, Pharmaceutical Executive at Gilead Sciences The COVID-19 pandemic forced the pharmaceutical industry to do what once seemed impossible: compress launch cycles that traditionally stretched over a decade into mere months. The ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In